Relevant bibliographies by topics / Myocardial infarction Chemotherapy

Academic literature on the topic 'Myocardial infarction Chemotherapy'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Myocardial infarction Chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Myocardial infarction Chemotherapy"

1

LAW, H. "Chemotherapy-induced myocardial infarction." European Heart Journal 17, no. 6 (June 2, 1996): 966–67. http://dx.doi.org/10.1093/oxfordjournals.eurheartj.a014984.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bissett, D., and S. B. Kaye. "Myocardial infarction after chemotherapy for testicular teratoma." Annals of Oncology 4, no. 5 (May 1993): 432. http://dx.doi.org/10.1093/oxfordjournals.annonc.a058529.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bachmeyer, Claude, Hervé Joly, and Roland Jorest. "Early Myocardial Infarction during Chemotherapy for Testicular Cancer." Tumori Journal 86, no. 5 (September 2000): 428–30. http://dx.doi.org/10.1177/030089160008600513.

Full text
Abstract:
A 36-year-old man with testicular cancer had an acute myocardial infarction during the first course of chemotherapy with bleomycin, etoposide and cisplatin. Since the patient had no significant risk factors for coronary heart disease, the infarction was likely to be attributable to the chemotherapy regimen. The physiopathological mechanisms of this causal relationship are discussed here.
APA, Harvard, Vancouver, ISO, and other styles
4

Kashiwagi, Yoshiyuki. "A Case of Acute Myocardial Infarction during Chemotherapy of Advanced Rectal Cancer." Nurse Media Journal of Nursing 8, no. 2 (March 4, 2019): 96. http://dx.doi.org/10.14710/nmjn.v8i2.18908.

Full text
Abstract:
Background:Cetuximab and irinotecan, levoforinate, 5-FU (FOLFIRI) are administered to advanced colorectal cancer. Although this regimen is standardized for recurrent metastatic colorectal cancer, the merger of myocardial infarction is rare.Purpose:The aim of this study is consider factors of myocardial infarction that developed during chemotherapy of colorectal cancer.Method:We conduct a retrospective study of cases in which myocardial infarction develops during chemotherapy in colorectal cancer on the basis of medical records, nursing records and physiological function test results.Case:A 80-year-old man was in chemotherapy with cetuximab + FOLFIRI in outpatient with multiple lung metastasis diagnosis after rectal cancer surgery.Result:Three days after the 38th administration, the patient visited an emergency outpatient mainly with complaints of dyspnea and back pain. Electrocardiogram was a finding that the lower wall infarction is suspected. The patient of bi-aspirin oral administration and chest pain 10 mg of morphine hydrochloride was injected via intravenous drip infusion, and it was transferred to a specialized cardiovascular hospital.Emergency coronary angiography was performed in the diagnosis of acute myocardial infarction, and percutaneous coronary intervention was performed because the left anterior descending branch complete occlusion was recognized. After thrombus aspiration, the balloon was dilated, the stent was placed, and reperfusion was successfully completed. The patient was discharged on the 10th disease day.In this case, it is thought that cetuximab + FOLFIRI synergistically induced hyperthrombogenicity, coronary plaque erosion, and acute myocardial infarction.It may also be necessary for interventions such as monitoring of risks in daily living by the medical care provider and guidance on risk avoidance behaviors.brief background of the topic and significance of the study.Conclusion:In this case, it is thought that cetuximab + FOLFIRI synergistically induced hyperthrombogenicity, coronary plaque erosion, and acute myocardial infarction. It may also be necessary for interventions such as monitoring of risks in daily living by the medical care provider and guidance on risk avoidance behaviors.
APA, Harvard, Vancouver, ISO, and other styles
5

Ozben, Beste, Ramazan Kurt, Huseyin Oflaz, Murat Sezer, Mert Basaran, Taner Goren, and Sabahattin Umman. "Acute Anterior Myocardial Infarction After Chemotherapy for Testicular Seminoma in a Young Patient." Clinical and Applied Thrombosis/Hemostasis 13, no. 4 (October 2007): 439–42. http://dx.doi.org/10.1177/1076029607303334.

Full text
Abstract:
Testicular cancer is the most common solid tumor among young men aged 15 to 35 years. Combination chemotherapy with cisplatin, etoposide, and bleomycin remains the mainstay of treatment. We present a 27-year-old man who presented with an acute anterior myocardial infarction during the second course of chemotherapy for seminoma. Because the patient had no significant risk factors for coronary heart disease, the infarction was likely caused by the chemotherapy regimen.
APA, Harvard, Vancouver, ISO, and other styles
6

Roy, Ambuj, Naveen Khanna, and Nagendra Boopathy Senguttuvan. "Rituximab-Vincristine Chemotherapy-Induced Acute Anterior Wall Myocardial Infarction with Cardiogenic Shock." Texas Heart Institute Journal 41, no. 1 (February 1, 2014): 80–82. http://dx.doi.org/10.14503/thij-12-2853.

Full text
Abstract:
We present a case of an elderly man with coronary artery disease who was diagnosed with non-Hodgkin lymphoma. Soon after the administration of chemotherapy, which included rituximab and vincristine, he developed acute myocardial infarction with cardiogenic shock. The condition was managed successfully with primary percutaneous coronary intervention. We briefly discuss the possible pathogenic mechanisms of chemotherapy-induced ischemic syndrome and the management of chemotherapy in patients with high cardiovascular risk.
APA, Harvard, Vancouver, ISO, and other styles
7

House, Kenneth W., Sheryl R. Simon, and Reginald P. Pugh. "Chemotherapy-induced myocardial infarction in a young man with hodgkin's disease." Clinical Cardiology 15, no. 2 (February 1992): 122–25. http://dx.doi.org/10.1002/clc.4960150214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bilir, Cemil, Hüseyin Engin, Yasemin Bakkal Temi, Bilal Toka, and Turgut Karabağ. "Acute Myocardial Infarction Caused by Filgrastim: A Case Report." Case Reports in Oncological Medicine 2012 (2012): 1–2. http://dx.doi.org/10.1155/2012/784128.

Full text
Abstract:
Common uses of the granulocyte-colony stimulating factors in the clinical practice raise the concern about side effects of these agents. We presented a case report about an acute myocardial infarction with non-ST segment elevation during filgrastim administration. A 73-year-old man had squamous cell carcinoma of larynx with lung metastasis treated with the chemotherapy. Second day after the filgrastim, patient had a chest discomfort. An ECG was performed and showed an ST segment depression and negative T waves on inferior derivations. A coronary angiography had showed a critical lesion in right coronary arteria. This is the first study thats revealed that G-CSF can cause acute myocardial infarction in cancer patients without history of cardiac disease. Patients with chest discomfort and pain who are on treatment with G-CSF or GM-CSF must alert the physicians for acute coronary events.
APA, Harvard, Vancouver, ISO, and other styles
9

Alici, Hayri, Fethi Yavuz, Suleyman Ercan, and Vedat Davutoglu. "Chemotherapy related myocardial infarction in a young patient with yolk sac tumor." International Journal of the Cardiovascular Academy 1, no. 1 (June 2015): 21–23. http://dx.doi.org/10.1016/j.ijcac.2015.07.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dieckmann, K. P., A. Gerl, J. Witt, and J. T. Hartmann. "Myocardial infarction and other major vascular events during chemotherapy for testicular cancer." Annals of Oncology 21, no. 8 (August 2010): 1607–11. http://dx.doi.org/10.1093/annonc/mdp597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Myocardial infarction Chemotherapy"

1

Lee, Ker-Wei, and 李克威. "Relevant Factors and the Risk of Acute Myocardial Infarction in Colorectal Cancer Patients Undergoing Chemotherapy." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/34237852354188732958.

Full text
Abstract:
碩士
中國醫藥大學
醫務管理學系碩士在職專班
102
Background: According to previous research, patients with cancer who received chemotherapy may develop acute myocardial infarction because of the cardiac toxicity resulting from chemotherapeutic agents. Among the 10 leading lethal cancers, colorectal cancer has been ranked third over the previous years. Thus, this study explored the risk of developing acute myocardial infarction in patients with colorectal cancer who received chemotherapeutic agents and investigated relevant factors. Methods: The National Health Insurance Research Database was used as the data source. Patients who were newly diagnosed with colorectal cancer during 2000 to 2009 were selected and observed throughout a follow-up until 2011. The case group comprised cancer patients who received or did not receive chemotherapy, and the control group comprised people who did not have cancer. A 1:5 propensity score matching method was employed, yielding 170,370 participants. A Cox proportional hazards model was used to analyze the relative risks and related factors for developing acute myocardial infarction in patients with colorectal cancer who received chemotherapy. Results: A comparison of the case group and the control group revealed significant differences (P < .05) among the variables, such as chemotherapy reception, age, economic status, regional characteristics, and health status. The risk of developing acute myocardial infarction in patients with colorectal cancer who received chemotherapy and who did not receive chemotherapy was respectively 0.64 times (95% confidence interval [CI]: 0.60–0.68) and 0.89 times (95% CI: 0.86–0.92) that of people without cancer. However, regardless of whether they had received chemotherapy, patients with colorectal cancer who achieved a Charlson Comorbidity Index (CCI) score of 4 or greater had higher risks of developing acute myocardial infarction than did people without cancer. The relative risk of developing myocardial infarction in patients with colorectal cancer who received chemotherapy was 0.80 times that of the patients with colorectal cancer who did not receive chemotherapy (95% CI: 0.77–0.82). Conclusions: The results indicated that patients with colorectal cancer who received or did not receive chemotherapy had lower risks of developing acute myocardial infarction than did people without cancer. However, having a higher CCI score significantly increased the risk of acute myocardial infarction. The risk of developing myocardial infarction in patients with colorectal cancer who received chemotherapy was lower than that of patients who did not receive chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Myocardial infarction Chemotherapy"

1

Taylor, George Jesse. Thrombolytic therapy for acute myocardial infarction. Boston: Blackwell Scientific Publications, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

R, Bates Eric, ed. Thrombolysis and adjunctive therapy for acute myocardial infarction. New York: Dekker, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

National Institute for Clinical Excellence. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction. London: National Institute for Clinical Excellence, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

The ACE inhibitor/myocardial infarction trials: From clinical trials to clinical practice. Beckenham: Publishing Initiatives Books, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1994), Hamburger Symposion (8th. Nitroglycerin 8: Basics, standard and elective applications. Edited by Mehmel H. C. Berlin: Walter de Gruyter, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Workshop on Nisoldipine in Coronary Artery Diseases and Myocardial Infarction (1992 London). Workshop on nisoldipine in coronary artery diseases and myocardial infarction: Papers presented at a workshop held in London, April 8, 1992, during the International Conference on Acute Myocardial Infarction. New York: Raven Health Care Communications, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

A, Abd-Elfattah Anwar-Saad, and Wechsler Andrew, eds. Purines and myocardial protection. Boston: Kluwer Academic Publishers, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1946-, Whelton Paul K., Whelton Andrew 1940-, and Walker W. Gordon 1926-, eds. Potassium in cardiovascular and renal medicine: Arrhythmias, myocardial infarction, and hypertension. New York: Dekker, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

N, Singh B., Wellens H. J. J, and Hiraoka Masayasu 1940-, eds. Electropharmacologic control of cardiac arrythmias: To delay conduction or to prolong refractoriness? Mt. Kisco, NY: Futura Pub., 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pharand, Chantal. The use of platelet glycoprotein IIB/IIIA receptor antagonists in the management of unstable angina and non-st-elevation myocardial infarction: A critical evaluation. [Toronto?: s.n., 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Myocardial infarction Chemotherapy"

1

Schwitter, Juerg, and Jens Bremerich. "Cardiac magnetic resonance in the intensive and cardiac care unit." In The ESC Textbook of Intensive and Acute Cardiovascular Care, edited by Marco Tubaro, Pascal Vranckx, Eric Bonnefoy-Cudraz, Susanna Price, and Christiaan Vrints, 246–64. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198849346.003.0021.

Full text
Abstract:
Current applications of cardiac magnetic resonance offer a wide spectrum of indications in the setting of acute cardiac care. In particular, cardiac magnetic resonance is helpful for the differential diagnosis of chest pain through the detection of ischaemia, myocardial stunning, myocarditis, including chemotherapy-induced myocarditis, and pericarditis. Also, Takotsubo cardiomyopathy and acute aortic diseases can be evaluated by cardiac magnetic resonance and are important differential diagnoses in patients with acute chest pain. In patients with restricted windows for echocardiography, according to guidelines, cardiac magnetic resonance is the method of choice to evaluate complications of an acute myocardial infarction. In an acute myocardial infarction, cardiac magnetic resonance allows for unique characterization of myocardial damage by quantifying necrosis, microvascular obstruction, oedema (i.e. areas at risk), and haemorrhage. These features will help us to understand better the pathophysiological events during infarction and will also allow us to assess new treatment strategies in acute myocardial infarction. To which extent the information on tissue damage will guide patient management is not yet clear, and further research is ongoing to address this issue. Recent studies also demonstrated the possibility to reduce costs in the management of acute coronary syndromes when cardiac magnetic resonance is integrated into the routine work-up. In the near future, applications of cardiac magnetic resonance will continue to expand in acute cardiac care units, as manufacturers are now strongly focusing on this aspect of user-friendliness. Finally, in the next decade or so, magnetic resonance imaging using other nuclei, such as fluorine and carbon, might become a reality in clinics, which would allow for metabolic and targeted molecular imaging with excellent sensitivity and specificity.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Myocardial infarction Chemotherapy"

1

Poniewierski, M., M. Barthels, and H. Poliwoda. "THE SAFETY AND EFFICACY OF A LOW MOLECULAR WEIGHT HEPARIN (FRAGMIN) IN THE PREVENTION OF DEEP VEIN THROMBOSIS IN MEDICAL PATIENTS: A RANDOMIZED DOUBLE-BLIND TRIAL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643224.

Full text
Abstract:
The safety and efficacy of 2500 anti-Factor Xa U of a low molecular weight heparin (Kabi 2165, Fragmin) subcutaneously once a day, and 5000 IU of standard unfractionated Heparin (KabiVitrum, Stockholm) subcutaneously twice daily as thromboprophylaxis was compared in 200 medical patients in a randomized double blind trial. According to the risk of DVT the patients were stratified before randomization in a high and low risk group. The high risk group consisted of 100 patients mainly with malignant diseases and/or previous history of thromboembolism, the low risk group of 100 patients with mainly myocardial infarction and/or coronary heart disease. The prophylaxis was given for seven to ten days. In 192 consecutive patients the clinical status and thermographic screening for DVT (leg temperature profiles, DeVeTherm) were daily evaluated. In two cases of suspected DVT and one case of suspected PE, the following phlebography or pulmonary scintigraphy were found to be negative. In the high risk group, one patient treated with Fragmin having a central venous catheter developed on day 10 symptoms of an arm vein thrombosis. There were no bleeding complications observed in either of the two treatment groups. Two patients with trombocytopenia (25.000 and 22.000/pl) due to chemotherapy and underlying malignant disease were successfully treated with Fragmin without developing any bleeding complications. In eight patients during Fragmin prophylaxis invasive diagnostic methods as heart catheterization, gastroscopy, bronchoscopy or spinal puncture were performed without noticing any bleeding events. 2500 anti-Factor Xa U of Fragmin gave plasma levels by anti-Factor Xa assay (S-2222, Kabi) of mean 0,1 U/ml when blood was sampled three to four hours after the subcutaneus application. There was no accumulation during the treatment periode observed.This study suggests that 2500 anti-Factor Xa U of Fragmin once daily is as safe and effective as 5000 IU of standard heparin twice daily in these medical patients. Especially in patients who need prophylaxis for a long time eg. with malignant disease, the once daily injection is welcomed.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Myocardial infarction Chemotherapy' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography